SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Ash Walia was appointed as Chief Financial Officer of Six Flags Entertainment Corporation, effective June 17, 2026, with a base salary of $690,000, target annual incentive of 100%, restricted stock units valued at $1,250,000, and annual equity grants of $1,869,000.
View raw filing on EDGAR →Erik Lundgren was appointed as Chief Executive Officer effective June 1, 2026, with a detailed employment agreement including a base salary of $685,000, performance bonuses, and an equity grant of 1,000,000 options. Dr. Daniel Vitt resigned as CEO concurrent with this appointment.
View raw filing on EDGAR →This Item 5.07 disclosure presents the complete voting results from Star Equity Holdings' Annual Meeting of Stockholders held on May 27, 2026, covering three proposals: election of seven directors, advisory approval of named executive officer compensation, and ratification of the independent auditor. The detailed vote tallies for each proposal and nominee are the core content of a shareholder_vote_results event.
View raw filing on EDGAR →ASPAC III received a notice from Nasdaq on May 20, 2026 stating that stockholders' equity fell below the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1), resulting in non-compliance with continued listing standards. The company has 45 days to submit a compliance plan and up to 180 days to evidence compliance, with no assurance of success. This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →La Rosa Holdings entered into a Securities Purchase Agreement on May 27, 2026, to issue up to 500 shares of Series D Convertible Preferred Stock at $1,000 per share ($250,000 closing immediately, with 250 shares optionally issuable upon filing the 2025 Form 10-K). The Series D Preferred includes conversion rights into common stock at a fixed price of $1.58 or an Alternate Conversion Price as low as 90% of 10-day VWAP, with a 125% uplift multiplier, creating significant dilution to existing shareholders.
View raw filing on EDGAR →Hoth Therapeutics, Inc. changed its corporate name to Rocket One Inc. and its ticker symbol from HOTH to RKTO, effective May 27, 2026. The company also formed and renamed a wholly-owned subsidiary from Rocket One Inc. to Rocket One.0 Inc. as part of the corporate restructuring.
View raw filing on EDGAR →New Horizon Aircraft entered into Securities Purchase Agreements on May 26, 2026, to sell 5,385,646 Class A ordinary shares and pre-funded warrants to purchase 4,574,514 additional shares for approximately $25.0 million in gross proceeds. The registered direct offering will result in substantial dilution to existing shareholders, with proceeds intended for Cavorite X7 prototype development and testing.
View raw filing on EDGAR →NewHold Investment Corp. III (SPAC) entered into a Business Combination Agreement with NewCleo Ltd. on May 26, 2026, whereby NewCleo will become the parent company through a two-step merger structure. The transaction includes significant equity restructuring, recapitalization, and PIPE investment components, representing a material change of control.
View raw filing on EDGAR →Oceanhawk Acquisition Corp., a special purpose acquisition company (SPAC), consummated its IPO on May 22, 2026, raising $160 million in gross proceeds and entering into material definitive agreements including underwriting, rights, trust, registration rights, and indemnity agreements as part of its formation and capitalization.
View raw filing on EDGAR →Oceanhawk issued 500,000 unregistered units to the Sponsor and The Benchmark Company, LLC at $10.00 per unit pursuant to Section 4(a)(2) of the Securities Act, generating $5 million in gross proceeds in a private placement concurrent with the IPO.
View raw filing on EDGAR →Six directors—Joseph Durnford, Ernest Miller, Jon Ryan, Mike Maggard, Dan Collingridge-Padbury, and Jonathan Nickell—were appointed to the board of Oceanhawk in connection with the IPO on May 20, 2026, with assignments to audit and compensation committees.
View raw filing on EDGAR →Borealis Foods received a notice from Nasdaq on May 21, 2026 stating that the Company no longer complies with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file the Q1 2026 Form 10-Q. The Company has until June 16, 2026 to submit a compliance plan and until October 12, 2026 to regain compliance.
View raw filing on EDGAR →The filing discloses the appointment of Karen Park as a director of Fortress Value Acquisition Corp. V, effective immediately on May 27, 2026, along with her concurrent appointment to the Audit Committee and Compensation Committee. The principal disclosed action is a person taking a role. While the filing also mentions compensatory arrangements (30,000 founder shares), the core event centers on the director appointment itself, which is material to investors as it affects board composition and governance of a SPAC.
View raw filing on EDGAR →Lululemon entered into a Cooperation Agreement with Dennis 'Chip' Wilson and affiliated entities on May 26, 2026, involving material changes to board composition, board declassification, and voting commitments that represent a significant shift in corporate governance and control dynamics.
View raw filing on EDGAR →Charlton Aria received a Notice from Nasdaq on May 22, 2026, for non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended March 31, 2026. This is a second notice following an earlier April 16, 2026 notice regarding failure to file the Form 10-K. The company has until June 15, 2026 to file the required reports or submit a compliance plan, with potential delisting consequences.
View raw filing on EDGAR →Dominari Holdings entered into inducement agreements with warrant holders on May 22, 2026, offering either cash exercise at a reduced price ($2.50 vs. $4.22) or exchange of Series B Warrants for Common Stock at a 10:3 ratio. The transaction involves material consideration—approximately $3.67 million in gross proceeds and ~150,000 shares issued—and materially restructures the Company's outstanding warrant obligations and capital structure. While not a traditional M&A transaction, this is a material definitive agreement that affects the registrant's equity and financial position.
View raw filing on EDGAR →Bit Digital entered into material financing arrangements totaling $100-150 million with Enovum NC-1 Venture, LLC (expandable to $150 million) and secured $50 million from Galaxy Digital to fund development of a high-performance computing data center in Madison, North Carolina. These arrangements, involving related parties and representing significant capital deployment for strategic infrastructure, constitute material transactions affecting the company's capital structure.
View raw filing on EDGAR →WhiteFiber entered into a $100 million (expandable to $150 million) Delayed Draw Term Loan Facility with Bit Digital Capital on May 20, 2026, disclosed under Item 1.01 (Entry Into A Material Definitive Agreement). While this is technically a financing arrangement rather than a traditional M&A transaction, the scale ($100M+), the strategic nature (funding HPC data center buildout in North Carolina), and the material impact on the company's capital structure and obligations make this a significant material event. The filing also notes fairness opinions from independent advisors and board approval, underscoring materiality. A secondary assignment of $20 million to B. Riley on May 26, 2026 further evidences the transaction's significance.
View raw filing on EDGAR →SoundHound AI held its annual meeting of stockholders on May 22, 2026, at which shareholders re-elected five directors (Dr. Keyvan Mohajer, James Hom, Larry Marcus, Diana Sroka, and Dr. Eric Ball) and ratified PricewaterhouseCoopers LLP as the independent auditor.
View raw filing on EDGAR →The Company entered into an equity distribution agreement with multiple underwriters to sell up to $300,000,000 of Class A common stock through an at-the-market (ATM) offering under a Form S-3ASR registration statement.
View raw filing on EDGAR →The Board unanimously adopted Second Amended and Restated Bylaws on May 25, 2026, removing a provision that previously allowed unauthorized or defective transactions to be cured through Board or stockholder approval, materially affecting stockholder derivative suit protections and corporate liability exposure.
View raw filing on EDGAR →This disclosure reports the consummation of an IPO generating $75 million in gross proceeds and a concurrent private placement of $3 million, with trust account establishment. While IPO completion is material to investors, the filing does not fit cleanly into the standard taxonomy categories—it is neither a traditional earnings release, M&A activity, nor a dilutive issuance (which typically refers to unregistered secondary offerings). The event is material but best classified as other_material given the specialized nature of SPAC IPO completion and trust account mechanics.
View raw filing on EDGAR →The filing discloses an amendment to the Certificate of Designation increasing authorized Series B Cumulative Convertible Preferred Stock from 397,222 to 572,222 shares (a 44% increase). While this is a structural/governance change disclosed under Item 5.03, the material substance is an expansion of convertible preferred equity capacity, which could signal dilution risk or capital-raising activity. This does not fit neatly into the more specific categories (it is not a dilutive issuance itself, nor a routine bylaw amendment), so other_material is most appropriate.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of TransAct Technologies' 2026 Annual Meeting of Stockholders held on May 26, 2026. The filing presents voting results for three proposals: election of six directors (Dillon, Dunning, Friedberg, Friedman, Hilario, and Olinger), ratification of CBIZ CPAs P.C. as independent auditor, and an advisory vote on executive compensation. All proposals passed with substantial majorities. Shareholder vote results are material to investors as they reflect governance outcomes and stockholder preferences.
View raw filing on EDGAR →The filing discloses stockholder approval of an Amended and Restated Certificate of Incorporation that effects board declassification and eliminates supermajority voting requirements, along with corresponding bylaw amendments. While Item 5.03 covers amendments to articles and bylaws, these governance changes are material to investors as they fundamentally alter board composition mechanics and voting thresholds, affecting shareholder rights and corporate control dynamics. This does not fit neatly into the more specific event categories (e.g., it is not an executive appointment, departure, or compensation matter), warranting classification as other_material.
View raw filing on EDGAR →This disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While Item 2.03 typically captures covenant breaches or material debt arrangements, this filing describes routine debt issuance activity that is material to the Bank's operations but does not fit cleanly into the covenant_breach category (no breach or default is disclosed). The Bank explicitly states "consolidated obligations issuance is material to the Bank," and Schedule A details committed issuances, making this a material event that warrants disclosure but falls outside the more specific event-type categories.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes totaling approximately $560 million across five separate issuances with varying maturities (2026–2034) and coupon rates (3.83%–5.08%). While Item 2.03 typically signals covenant_breach or debt acceleration events, this filing describes routine debt issuance by a Federal Home Loan Bank in the ordinary course of business—a material financing activity that does not fit the specific covenant_breach taxonomy (which implies a triggering default or acceleration). The disclosure is material to investors assessing the registrant's capital structure and funding activities, but the event itself is a standard debt offering rather than a breach or distress signal.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligation bonds totaling approximately $390 million across three debt securities (trade dates 5/20–5/22/2026, maturing 2027–12/2027). While the filing explicitly states "consolidated obligations issuance is material to the Bank," the event does not fit cleanly into the standard taxonomy: it is neither a covenant breach (no default triggered), nor a dilutive equity issuance, nor a restatement or going-concern disclosure. The creation of direct financial obligations through routine debt issuance by a Federal Home Loan Bank is material to investors but represents ordinary course funding activity rather than an extraordinary event, warranting classification as other_material.
View raw filing on EDGAR →The filing discloses Phreesia's financial results for the fiscal first quarter ended April 30, 2026 through a press release and stakeholder letter furnished as exhibits. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides periodic financial performance data.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from PCB Bancorp's annual meeting held on May 27, 2026. The filing reports voting outcomes on three proposals: election of eight directors, an advisory vote on executive compensation (approved with 8,493,476 votes for), and ratification of Crowe LLP as independent auditor (approved with 10,015,747 votes for). This is a quintessential Item 5.07 disclosure and is material as it reflects shareholder approval of key governance matters.
View raw filing on EDGAR →The filing discloses financial results for the fourth quarter and full fiscal year ended March 31, 2026, with the press release attached as Exhibit 99.1. This is a standard earnings release announcement under Item 2.02, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →The filing discloses results of Business First Bancshares' annual shareholder meeting held on May 21, 2026, under Item 5.07. The company reports voting outcomes on three proposals: election of 16 directors, non-binding advisory approval of named executive officer compensation, and ratification of Forvis Mazars, LLP as independent auditor. The detailed voting tallies for each director and proposal are provided, with 72.62% shareholder attendance.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on May 27, 2026, filed under Item 5.07. The filing presents detailed vote tallies for three proposals: election of two Class III Directors (John Deane and W. Matt Ralls), ratification of Grant Thornton LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure includes vote counts (For, Against, Withheld, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures required by Item 5.07.
View raw filing on EDGAR →The filing discloses positive topline results from a Phase 3 clinical trial (ENHANCE trial) for BRIUMVI®, a marketed therapeutic. While technically a clinical trial result rather than financial earnings, this represents material clinical/commercial news about a key product that would affect investor assessment of the company's pipeline and commercial prospects. The press release announcement of trial results is the core disclosure, making this functionally equivalent to an earnings-type announcement in the biotech context.
View raw filing on EDGAR →The filing discloses the appointment of Michael Pruitt to the Board of Directors on May 20, 2026. Although the Item 5.02(d) heading references both departures and appointments, the prose centers exclusively on Pruitt's election as a director, with detailed background on his extensive public company leadership experience and expertise in emerging technology. This is a clear director appointment event.
View raw filing on EDGAR →National Healthcare Corp entered into a material acquisition of assets and real property from National Health Investors, Inc. pursuant to a Purchase and Sale Agreement dated April 21, 2026, with integrated financing through a $475 million term loan and $50 million revolving credit facility expected to close simultaneously in Q3 2026.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 annual meeting held on May 27, 2026, covering three proposals: election of seven directors, advisory vote on named executive officer compensation, and ratification of the independent auditor (Accuity LLP). The filing presents voting tallies for each proposal, which is the core content of Item 5.07 disclosures and constitutes material information about corporate governance outcomes.
View raw filing on EDGAR →Arbutus Biopharma held its Annual Meeting of Shareholders on May 26, 2026, with voting results on four proposals: director elections, approval of the 2026 Omnibus Share and Incentive Plan, an advisory vote on named executive officer compensation, and appointment of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →The filing discloses demand letters from Whitehawk Capital Partners asserting two events of default under an $80 million Credit Agreement dated July 29, 2025, including alleged breaches of Sections 9.8 and 9.18 and an insolvency proceeding triggering Section 11.1(l). Whitehawk claims all obligations became automatically due and payable, with interest accruing at default rates since August 19, 2025, and has filed litigation to enjoin transfer of collateral. This is a classic covenant breach and acceleration event under Item 2.04.
View raw filing on EDGAR →Everpure issued a press release on May 27, 2026 disclosing financial results for the quarter ended May 3, 2026, with the press release furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Expensify's 2026 Annual Meeting of Stockholders held on May 22, 2026. The filing presents voting results for four proposals: election of eight directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of reverse stock split and authorized share reduction. All proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →The Company disclosed non-reliance on previously issued financial statements in Item 4.02(a), citing failures to follow US GAAP in the timing of legal fee recognition and revenue recognition errors across three quarterly periods (March 31, June 30, and September 30, 2025 Form 10-Qs). The auditor Michael Gillespie & Associates identified that $9,840 in legal expenses should have been recorded when services were performed rather than when invoiced, and there were additional revenue recognition and prepaid fee classification errors. The Company anticipates restating these financial statements by June 30, 2026, which constitutes a material accounting restatement.
View raw filing on EDGAR →SOBR Safe received a Nasdaq deficiency letter on March 19, 2026 for failing to maintain the $1.00 minimum bid price requirement for 30 consecutive business days. Although the company obtained a stay and a conditional extension until September 15, 2026 to regain compliance (contingent on completing a business combination with Clean World Ventures and demonstrating compliance with Initial Listing Rules), the filing explicitly discloses the delisting risk and the conditions precedent to continued listing, which is the core substance of Item 3.01.
View raw filing on EDGAR →The filing discloses entry into an At-The-Market (ATM) Issuance Sales Agreement on May 26, 2026, permitting the Company to offer and sell up to $5,000,000 of common stock through Alexander Capital. This is a classic dilutive equity issuance under Item 1.01. The forward-looking statements also reference the Company's need to regain compliance with Nasdaq's Stockholders' Equity Requirement, signaling financial stress and the use of equity issuance as a capital-raising mechanism.
View raw filing on EDGAR →Tonix Pharmaceuticals announced publication of a peer-reviewed Phase 1 clinical trial manuscript for TNX-1500 in the Journal of Clinical Immunology, demonstrating positive immunosuppressive efficacy in blocking T cell-dependent antibody responses at all tested doses. This clinical development milestone is material to investors assessing the company's pipeline progress and de-risking of the lead drug candidate.
View raw filing on EDGAR →The filing discloses entry into Amendment No. 1 to an Exclusive License Agreement with MIRALOGX LLC on May 21, 2026 (Item 1.01). The amendment materially expands the Company's exclusive licensed territory for Ketamir-2 from the US, Canada, and Mexico to all countries with patent rights, and expands the licensed patent portfolio internationally across multiple jurisdictions. While the core economic terms remain unchanged, the territorial and patent scope expansion represents a material modification to the Company's rights and development strategy for a key asset, supporting continued global development and commercialization of Ketamir-2.
View raw filing on EDGAR →The filing discloses termination of an exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206 molecules, exercised pursuant to a suspension letter agreement dated May 30, 2025. This represents a material change in the Company's intellectual property licensing arrangements and strategic partnerships, affecting the Company's ability to develop and commercialize key assets.
View raw filing on EDGAR →bioAffinity Technologies disclosed receipt of a patent allowance notification from the Mexican Institute of Industrial Property for a method related to lung cancer prediction using flow cytometry. While this is a positive intellectual property development, it does not fit cleanly into the standard 8-K event taxonomy (not earnings, M&A, executive changes, impairments, litigation, or cybersecurity). Patent allowances can be material to biotech/diagnostic companies' competitive positioning and valuation, warranting disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →This 8-K discloses the results of Shuttle Pharmaceuticals' 2026 Annual Meeting of Stockholders held on May 21, 2026, including voting outcomes on five proposals: election of four directors, ratification of Forvis Mazars as independent auditor, advisory vote on executive compensation, authorization for reverse stock splits (1-for-2 to 1-for-150), and meeting adjournment. All proposals were approved. This is a classic Item 5.07 shareholder vote results disclosure with detailed vote tallies and quorum information.
View raw filing on EDGAR →SINTX received a notice from Nasdaq on May 22, 2026 (Item 3.01) stating the company is not in compliance with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. The company reported only $904,000 in stockholders' equity as of March 31, 2026 and does not meet alternative listing standards. The company has 45 days to submit a compliance plan or faces delisting risk, making this a material disclosure of continued listing failure under Item 3.01.
View raw filing on EDGAR →